Helix Acquisition Corp. II has issued proforma combined financial statements related to its recent merger and acquisition (M&A) transaction with BridgeBio Oncology Therapeutics, Inc. The transaction, which was finalized on August 11, 2025, involved Helix merging with BridgeBio Oncology, resulting in the formation of a combined entity now listed on the Nasdaq under the ticker symbol "BBOT." The financial statements highlight that prior to the closing of this de-SPAC transaction, Helix conducted a private placement financing, raising $260.9 million. The combined company received a total of $366.8 million, accounting for the PIPE financing and unredeemed cash, while also reflecting the transaction costs incurred by Helix. This strategic move aims to bolster the company's mission to develop transformative medicines targeting genetic diseases and cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.